Life Sciences & Health Tech

Life Sciences & Health Tech

Pharmaceuticals and medical technology help improve the quality of life for an increasing number of people. Medical treatments, instruments and aids are becoming more and more necessary as the population ages. The current trend is towards personalised medicines and technologies that, while highly effective, are expensive to develop. At the same time, large buyers are monitoring their costs, and changes to the distribution system for medicines are being debated.

The pharmaceuticals industry and the distribution of pharmaceuticals are guided by strict rules covering everything from R&D to marketing. The regulation of medical technology is also approaching that of the pharmaceuticals industry. When health and safety are at stake, it is vital to operate irreproachably.

We help pharmaceutical and medical technology companies secure their rights. We handle patent litigation and trials relating to authority decisions with years of experience. We have solid expertise in marketing law, public procurement, and regulations pertaining to pharmacy.

We also assist companies and investors specialising in the medical, healthcare and health technology sectors with mergers and acquisitions, private equity and venture capital investments, financing and various industrial projects.

Our clients range from technology and growth companies, and pharmaceutical companies to healthcare providers. We also have a long track record of advising venture capital and private equity firms specialising in the healthcare and life sciences sector.

Latest references

We advised Aurevia Oy, a portfolio company of French private equity sponsor Mérieux Equity Partners, in a strategic reorganisation that involved splitting Aurevia and its parent companies into two independent groups of companies and reorganisation of its existing debt-financing arrangements. Following the reorganisation, the newly formed Aurevia continues as a leading provider of Contract Research Organization (CRO) and Quality Assurance and Regulatory Affairs (QARA) services, while the newly formed Labquality focuses on delivering External Quality Assessment (EQA) services. Aurevia serves operators in the medical devices, in vitro diagnostics and pharmaceutical sectors. Labquality’s customers include clinical laboratories and social and healthcare organisations. The reorganisation positions Aurevia and Labquality to allocate investments more effectively, accelerate growth within their respective customer segments, and respond to evolving market and client needs. The transaction was implemented through multiple parallel demergers and required comprehensive legal and tax structuring across several jurisdictions. Our team supported Aurevia throughout the planning and implementation phases, covering corporate, tax, employment law, and regulatory matters, as well as the optimisation of each group’s financing structure.
Case published 7.4.2026
We advised Oy Finnsusp Ab in the sale of its eyeglass lens business to IXI Optics Oy, subsidiary of a Finnish technology company IXI Eyewear. Finnsusp has been the only Finnish company manufacturing eyeglass lenses for over 35 years. Following the sale of its business, the company will focus on its international core business, specifically on the development and manufacturing of dry eye products and contact lens care solutions. Oy Finnsusp Ab (Piiloset) is a Finnish family-owned medical device manufacturer founded in 1978. In addition to Finland, the company’s products are sold in more than 35 countries in Europe, South and North America, the Middle East, and Africa. IXI Eyewear Oy is a Finnish technology startup that develops dynamic smart glasses based on liquid crystal technology. 
Case published 7.8.2025
We acted as Finnish legal adviser to KKR in connection with its acquisition of the entire share capital of Karo Healthcare from EQT. The transaction follows Karo’s significant strategic transformation from a Nordic specialty pharma business into a leading pan-European consumer healthcare platform, with an attractive product portfolio spanning core categories such as Skin Health, Foot Health, and Intimate Health, as well as Digestive Health and Vitamins, Minerals & Supplements. KKR & Co. Inc. (NYSE: KKR), is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds.  Completion of the transaction is subject to customary conditions and regulatory approvals. The transaction is expected to close in the coming months.
Case published 17.4.2025
We successfully represented Trety AB in a dispute and settlement negotiations concerning an agreement for development and production of communication devices for the healthcare sector. Eventually, the parties reached an amicable settlement to the full satisfaction of our client and thus the parties avoided an extensive arbitral proceeding. Trety AB is a global company that provides its customers with solutions for development, industrialization and production of electronics. Trety AB has over 30 years’ experience from IT, electronics and telecommunication industries.
Case published 11.2.2025